RUA Life Sciences PLC Notice of Results and Investor Presentation (5909R)
07 Julio 2022 - 1:00AM
UK Regulatory
TIDMRUA
RNS Number : 5909R
RUA Life Sciences PLC
07 July 2022
7 July 2022
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Notice of Results and Investor Presentation
RUA Life Sciences, the holding company of a group of medical
device businesses focused on the exploitation of the patented
long-term implantable biostable polymer, Elast-Eon(TM) , announces
the Group will release its audited annual results for the year
ended 31 March 2022 on 11 July 2022.
The Group will also conduct an investor presentation which will
follow the publication of the Group's final results. The event will
take place at 2.00pm on Monday 18 July with Bill Brown (Chairman)
and Caroline Stretton (Group Managing Director) presenting from the
Company.
The online presentation is open to all existing and potential
shareholders. Questions can be submitted during the presentation to
be addressed at the end.
To register for the event, please visit
www.equitydevelopment.co.uk/news-and-events/rua-life-sciences-fyresults-18july2022.
A recording of the presentation will be available shortly
afterwards on the Equity Developments website.
For further information contact:
RUA Life Sciences plc
Bill Brown, Chairman Tel: +44 (0) 77 3071 8296
Caroline Stretton, Group Managing Director Tel: +44 (0) 7789
901269
Cenkos Securities plc (Nominated Adviser and Broker) Tel: +44
(0) 20 7397 8900
Giles Balleny/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
improving and enabling medical devices with Elast-Eon(TM) , the
world's leading long-term implantable polyurethane.
Whether it is licensing Elast-Eon(TM) , manufacturing a device
or component or developing next generation medical devices, a RUA
Life Sciences business is pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 8
million implants and over 15 years of successful clinical use,
RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units are:
RUA Medical : End-to-end contract developer and manufacturer
of medical devices and implantable fabric specialist.
RUA Biomaterials Licensor of Elast-Eon(TM) polymers to the medical
: device industry.
RUA Vascular: Commercialisation of open surgical vascular
grafts and patches
RUA Structural Development of polymeric leaflet systems for
Heart : heart valves.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORRFMFTMTJMBJT
(END) Dow Jones Newswires
July 07, 2022 02:00 ET (06:00 GMT)
Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Rua Life Sciences (LSE:RUA)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
